Navigation Links
The Leukemia & Lymphoma Society Targets Research in Four Critical Areas of Unmet Medical Need
Date:12/14/2010

WHITE PLAINS, N.Y., Dec. 14, 2010 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is taking an aggressive approach to tackling the challenge of improving outcomes for patients with cancers that remain stubbornly resistant to treatment.  As it has for more than 62 years, LLS will continue to accept applications from the world's best and brightest scientists to advance progress in all areas of blood cancer, and award grants based on merit.  In addition LLS has identified four specific areas of need, and is soliciting applications from scientists and physicians who are working on these difficult problems.

"We are charting the course by identifying and prioritizing the areas of need and directing funding to research that shows the most promise for improving survival and quality of life for patients with these particular diseases," said Louis DeGennaro, Ph.D., LLS chief mission officer.  "LLS wants to deliver better treatments, faster, to patients, and we have developed an innovative, strategic approach to achieve this goal."

LLS is issuing requests for proposals (RFP) from researchers working in the following areas:

  • Identification and characterization of the leukemic stem cell in acute myeloid leukemia and myelodysplastic syndrome and the identification of potential targeted therapies
  • Novel therapeutic strategies for non-cutaneous T-cell lymphoproliferative disorders
  • Development of therapeutic strategies for the high risk myeloma patient
  • Mechanisms underlying long term and late effects resulting from cancer treatment and the development measures to significantly reduce or prevent these toxicities

  • Applications responsive to these RFPs should be submitted under LLS's Translational Research Program, a program designed to help accelerate the movement of promising discoveries from the lab to the clinic.  A detailed description of the LLS Translational Research Program and application instructions are available here.

    About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

    Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.Contact: Andrea Greif(914) 821-8958andrea.greif@lls.org
    '/>"/>

    SOURCE The Leukemia & Lymphoma Society
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
    2. Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
    3. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
    4. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
    5. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
    6. Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
    7. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
    8. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
    9. Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
    10. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
    11. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
    (Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
    (Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
    (Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
    (Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
    (Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
    Breaking Medicine News(10 mins):